7 + 3	7 days of cytarabine, 3 days of an anthracycline antibiotic
ALL	Acute lymphoblastic leukaemia
AML	Acute myeloid leukaemia
APL	Acute promyelocytic leukaemia
ATM	Ataxia telangiectasia mutated
ATO	Arsenic trioxide
BCL2	B-cell lymphoma 2
CD34+	Marker of human HSC
CML	chronic myeloid leukaemia
DUOX	Dual Oxidase
FDA	Food and Drug Administration
FLT3	Fms-like tyrosine kinase 3
GSH	Glutathione
H2O2	Hydrogen peroxide
HIF	Hypoxia inducible factor
HO•-	hydroxyl radical
HSC	Haematopoietic stem cells
IDH	Isocitrate dehydrogenase
IDH1/2	Isocitrate Dehydrogenase
ITD	Internal tandem duplications
JAK	Janus kinases
MAPK	Mitogen-activated protein kinase
MPN	Myeloproliferative neoplasms
mTOR	Mammalian target of rapamycin
NAC	N-acetyl-L-cysteine
NADPH	Nicotinamide adenine dinucleotide phosphate (reduced form)
NOX	NADPH Oxidase
NPM1	Nucleophosmin 1
O2•-	Superoxide
Prdxs	Peroxiredoxins
PTM	Posttranslational modifications
PTP	Protein tyrosine phosphatase
PTPRC	Protein tyrosine phosphatase, receptor C
PTPRJ	Protein tyrosine phosphatase, receptor J
RacRNS	Ras-related C3 botulinum toxin substrateReactive nitrogen species
ROS	Reactive oxygen species
SHP1	Src homology region 2 domain-containing phosphatase 1 (SHP-1)
SOD	Superoxide dismutase
STAT5	Signal transducer and activator of transcription 5
TKD	Tyrosine kinase domain
TSC	Tuberous sclerosis complex
TKD	Tyrosine kinase domain